首頁 > 市場調查報告書 > 醫療設備

體外診斷液體活檢

市場調查報告書

商品編碼

1393900

歐洲基於EV的液態切片市場－分析與預測（2023-2032）

Europe EV-Based Liquid Biopsy Market - Analysis and Forecast, 2023-2032

出版日期: 2023年12月08日 | 出版商:

BIS Research | 英文 82 Pages | 商品交期: 1-5個工作天內

價格

簡介目錄圖表

2022年歐洲基於EV的液體活體組織切片市場規模為1888萬美元，預計在2023-2032年預測期間將以20.30%的年複合成長率擴大，到2032年將達到11534萬美元。

歐洲基於EV的液體活體組織切片市場預計將受到持續的技術進步、醫療保健提供者越來越多的採用以及對個人化醫療的日益關注的推動。

主要市場統計資料
預測期	2023-2032
2023年評估	2185萬美元
2032年預測	11534萬美元
年複合成長率	20.3%

與傳統切片檢查技術相比，基於EV的液體活體組織切片具有許多優勢，並徹底改變了疾病診斷和監測。由於其非侵入性、即時監測能力以及疾病早期診斷的潛力，它徹底改變醫療保健診斷領域。基於EV的液體活體組織切片改善患者的治療效果，降低與醫療保健相關的成本，並提供一種侵入性較小且更容易監測和診斷疾病（包括癌症）的方法。此外，Bio-Techne Corporation、QIAGEN NV 和 Thermo Fisher Scientific Inc. 等許多現有公司的進入預計將促進市場擴張。

此外，基於電動車的液體活體組織切片市場的擴張創造經濟機會，鼓勵市場參與企業與學術機構合作，並激發研發力度。

本報告研究了歐洲基於電動車的液體活體組織切片市場，概述了市場、國家趨勢以及進入市場的公司概況。

The Europe EV-based liquid biopsy market was valued at $18.88 million in 2022 and is anticipated to reach $115.34 million by 2032, witnessing a CAGR of 20.30% during the forecast period 2023-2032. The Europe EV-based liquid biopsy market is expected to be driven by ongoing technological advancements, increasing adoption by healthcare providers, and a growing focus on personalized medicine.

KEY MARKET STATISTICS
Forecast Period	2023 - 2032
2023 Evaluation	$21.85 Million
2032 Forecast	$115.34 Million
CAGR	20.3%

Market introduction

The use of EV-based liquid biopsy, that offers many advantages over conventional biopsy techniques, has transformed the diagnosis and monitoring of disease. The field of healthcare diagnostics has been revolutionized by its non-invasiveness, real-time monitoring capabilities, and potential for early disease diagnosis. EV-based liquid biopsy has improved patient outcomes, decreased expenses associated with healthcare, and provided a less intrusive and more accessible means of monitoring and diagnosing diseases, including cancer. Furthermore, the market expansion is anticipated to be aided by the entry of many established companies, including Bio-Techne Corporation, QIAGEN N.V., and Thermo Fisher Scientific Inc.

In addition, the market expansion for EV-based liquid biopsies has created economic opportunities, prompted industrial participants to collaborate with academic institutions, and sparked research and development efforts.

Market Segmentation

Segmentation 1: by Country

Germany
U.K.
France
Italy
Spain
Rest-of-Europe"

How can this report add value to an organization?

Growth/Marketing Strategy: EV-based liquid biopsy has tremendous growth potential due to its ability to revolutionize non-invasive cancer detection and monitoring. By analyzing the cargo of EVs, researchers can gain insights into the presence, type, and characteristics of tumors without directly accessing the tumor site.

Competitive Strategy: Key players in the EV-based liquid biopsy market have been analyzed and profiled in the study, including manufacturers. Moreover, a detailed competitive benchmarking of the players operating in the EV-based liquid biopsy market has been done to help the reader understand how players stack against each other, presenting a clear market landscape.

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and regional presence.

Some of the prominent names in this market are:

Abcam plc
Qiagen N.V.

Malvern Panalytical Ltd.
Lonza Group AG

1 Definition

1.1 Inclusion and Exclusion Criteria

2 Research Scope

2.1 Key Questions Answered in the Report:

3 Research Methodology

3.1 EV-Based Liquid Biopsy Market: Research Methodology
3.2 Primary Data Sources
3.3 Secondary Data Sources
3.4 Market Estimation Model
3.5 Criteria for Company Profiling

4 Markets Overview

4.1 Market Introduction
4.2 Current and Future State of EV-Based Liquid Biopsy in Industries
4.3 Current Market Size and Growth Potential, $Million, 2022-2032
4.4 COVID-19 Impact on EV-based Liquid Biopsy Market
- 4.4.1 Impact on Operations
- 4.4.2 COVID-19 Impact: Current Scenario of the Market

5 Methods of EV Isolation and Analysis

5.1 Overview
- 5.1.1 Evs Introduction
5.2 Isolation Methods
- 5.2.1 EV Isolation Techniques Utilizing Ultracentrifugation Methods
  - 5.2.1.1 Differential Ultracentrifugation
  - 5.2.1.2 Density Gradient Centrifugation
  - 5.2.1.3 Moving Zone or Rate-Zonal Centrifugation
  - 5.2.1.4 Isopycnic Centrifugation
- 5.2.2 EV Isolation Techniques Utilizing Size-Based Methods
  - 5.2.2.1 Ultrafiltration
  - 5.2.2.2 Sequential Filtration
  - 5.2.2.3 Size Exclusion Chromatography (SEC)
  - 5.2.2.4 Flow Field-Flow Fractionation (FFFF)
  - 5.2.2.5 Hydrostatic Filtration Dialysis (HFD)
- 5.2.3 EV Isolation Techniques Utilizing Immunoaffinity Methods
  - 5.2.3.1 Enzyme-Linked Immunosorbent Assay (ELISA)
  - 5.2.3.2 Magneto-Immunoprecipitation
- 5.2.4 EV Isolation Techniques Utilizing Precipitation Methods
  - 5.2.4.1 Polyethylene Glycol (PEG) Precipitation
  - 5.2.4.2 Lectin Induced Agglutination
- 5.2.5 EV Isolation Techniques Utilizing Microfluidic Technology
- 5.2.6 EV Isolation Techniques Utilizing Commercial Kits
- 5.2.7 Advantages and Disadvantages of the EV Isolation Methods
- 5.2.8 Novel Approaches for Exosome Isolation
5.3 Analysis Methods
- 5.3.1 Advantages and Disadvantages of Analysis Methods for Evs

6 Industry Insights

6.1 Overview
6.2 Legal Requirements in the U.S.
6.3 Legal Requirements and Frameworks in Europe
6.4 Legal Requirements and Frameworks in Asia-Pacific
6.5 Reimbursement Scenario

7 Market Dynamics

7.1 Overview
7.2 Impact Analysis
7.3 Market Drivers
- 7.3.1 Abundance and Remarkable Stability of Exosomes Compared to CfDNA or CTCs
- 7.3.2 Amplified Funding and Dedicated Research Efforts
- 7.3.3 Rising Prevalence of Cancers
7.4 Market Restraints
- 7.4.1 Lack of Standardized EV Isolation and Characterization Protocols
- 7.4.2 Lack of Precise EV Subtype Classification and Biomarkers Validation
7.5 Market Opportunities
- 7.5.1 Advancements in EV-Based Liquid Biopsy Technologies
- 7.5.2 Development of New EV-Based Biomarkers
- 7.5.3 Approved Products in the Market

8 EV-Based Liquid Biopsy Market (by Region), $Million, 2022-2032

8.1 Overview
8.2 Europe
- 8.2.1 Germany
- 8.2.2 U.K.
- 8.2.3 France
- 8.2.4 Italy
- 8.2.5 Spain
- 8.2.6 Rest-of-Europe

9 Company Profiles

9.1 Company Overview
- 9.1.1 Abcam plc
  - 9.1.1.1 Company Overview
  - 9.1.1.2 Role of Abcam plc in the EV-Based Liquid Biopsy Market
  - 9.1.1.3 Major Products: Key Specifications
  - 9.1.1.4 Key Competitors
  - 9.1.1.5 Analyst Perspective
- 9.1.2 Qiagen N.V.
  - 9.1.2.1 Company Overview
  - 9.1.2.2 Role of Qiagen N.V. in the EV-Based Liquid Biopsy Market
  - 9.1.2.3 Major Products: Key Specifications
  - 9.1.2.4 Key Competitors
  - 9.1.2.5 Analyst Perspective
- 9.1.3 Malvern Panalytical Ltd
  - 9.1.3.1 Company Overview
  - 9.1.3.2 Role of Malvern Panalytical Ltd in the EV-Based Liquid Biopsy Market
  - 9.1.3.3 Major Products: Key Specifications
  - 9.1.3.4 Key Competitors
  - 9.1.3.5 Analyst Perspective
- 9.1.4 Lonza Group AG
  - 9.1.4.1 Company Overview
  - 9.1.4.2 Role of Lonza Group AG in the EV-Based Liquid Biopsy Market
  - 9.1.4.3 Major Products: Key Specifications
  - 9.1.4.4 Key Competitors
  - 9.1.4.5 Analyst Perspective

簡介目錄圖表

List of Figures

Figure 1: EV-Based Liquid Biopsy Market (by Offering), $Million, 2022-2032
Figure 2: EV-Based Liquid Biopsy Market (by End User), $Million, 2022 and 2032
Figure 3: EV-Based Liquid Biopsy Market (by Region), 2022
Figure 4: EV-Based Liquid Biopsy Market Methodology
Figure 5: Primary Research Methodology
Figure 6: Bottom-Up Approach (Segment-Wise Analysis)
Figure 7: Top-Down Approach (Segment-Wise Analysis)
Figure 8: EV-Based Liquid Biopsy Market, $Million, 2022-2032
Figure 9: Subtypes of Evs
Figure 10: Methods of EV-Isolation from Biofluids
Figure 11: Workflow of Differential Ultracentrifugation for Exosome Isolation
Figure 12: Methods of EV-Analysis
Figure 13: EV-Based Liquid Biopsy Market - Market Dynamics
Figure 14: Structure of Evs Enveloped by Protective Lipid Membrane
Figure 15: Number of Research Publications on Exosomes, 2015-2021
Figure 16: Share of New Cancer Cases, 2020
Figure 17: Number of Cancer Cases, 2020
Figure 18: Currently Investigated Circulating Biomarkers Associated with Evs
Figure 19: EV-Based Liquid Biopsy Market Snapshot (by Region)
Figure 20: EV-Based Liquid Biopsy Market (by Region), $Million, 2022-2032
Figure 21: Europe EV-Based Liquid Biopsy Market, $Million, 2022-2032
Figure 22: Europe: Market Dynamics
Figure 23: Europe EV-Based Liquid Biopsy Market (by Country), $Million, 2022-2032
Figure 24: Germany EV-Based Liquid Biopsy Market, $Million, 2022-2032
Figure 25: U.K. EV-Based Liquid Biopsy Market, $Million, 2022-2032
Figure 26: France EV-Based Liquid Biopsy Market, $Million, 2022-2032
Figure 27: Italy EV-Based Liquid Biopsy Market, $Million, 2022-2032
Figure 28: Spain EV-Based Liquid Biopsy Market, $Million, 2022-2032
Figure 29: Rest-of-Europe EV-Based Liquid Biopsy Market, $Million, 2022-2032
Figure 30: Total Number of Companies Profiled
Figure 31: Abcam plc: Product Portfolio
Figure 32: Qiagen N.V.: Product Portfolio
Figure 33: Malvern Panalytical Ltd: Product Portfolio
Figure 34: Lonza Group AG: Product Portfolio